WO2021145321A1 - 細胞の高密度培養方法 - Google Patents
細胞の高密度培養方法 Download PDFInfo
- Publication number
- WO2021145321A1 WO2021145321A1 PCT/JP2021/000746 JP2021000746W WO2021145321A1 WO 2021145321 A1 WO2021145321 A1 WO 2021145321A1 JP 2021000746 W JP2021000746 W JP 2021000746W WO 2021145321 A1 WO2021145321 A1 WO 2021145321A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- day
- cell
- medium
- culture
- Prior art date
Links
- 238000004113 cell culture Methods 0.000 title claims abstract description 10
- 229960001231 choline Drugs 0.000 claims abstract description 21
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims description 111
- 239000002609 medium Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 32
- 210000000130 stem cell Anatomy 0.000 claims description 24
- 239000013028 medium composition Substances 0.000 claims description 20
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 18
- 210000004504 adult stem cell Anatomy 0.000 claims description 10
- 238000004114 suspension culture Methods 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 239000006143 cell culture medium Substances 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 238000012136 culture method Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 108010009583 Transforming Growth Factors Proteins 0.000 description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000004966 intestinal stem cell Anatomy 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002514 epidermal stem cell Anatomy 0.000 description 2
- -1 etc.) Chemical compound 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NLOGSHMIAWCODV-UHFFFAOYSA-N 2-piperazin-4-ium-1-ylethanesulfonate Chemical compound OS(=O)(=O)CCN1CCNCC1 NLOGSHMIAWCODV-UHFFFAOYSA-N 0.000 description 1
- KZSXRDLXTFEHJM-UHFFFAOYSA-N 5-(trifluoromethyl)benzene-1,3-diamine Chemical compound NC1=CC(N)=CC(C(F)(F)F)=C1 KZSXRDLXTFEHJM-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Natural products O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- DQKGOGJIOHUEGK-UHFFFAOYSA-M hydron;2-hydroxyethyl(trimethyl)azanium;carbonate Chemical compound OC([O-])=O.C[N+](C)(C)CCO DQKGOGJIOHUEGK-UHFFFAOYSA-M 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
Definitions
- the present invention relates to a high-density culture method for cells, and more particularly to a high-density culture method for cells by adding choline.
- Patent Document 1 reports a method for culturing stem cells, which comprises treating the stem cells with a ROCK inhibitor in a medium.
- Patent Document 2 reports a high-density culture method of animal cells by adding glucose and / or a specific amino acid to a medium in 2018 (Patent Document 2).
- Patent Document 2 The method described in Patent Document 2 is one of the very excellent methods as a high-density culture method, but this time, the present inventors reexamined the method and developed a more preferable high-density culture method. I tried.
- the present inventors have found that cell proliferation can be promoted extremely easily by simply adding choline among various medium components during high-density culture of cells.
- the present invention has been completed by further research based on the findings. That is, the present invention is as follows.
- a method for culturing cells which comprises adding choline to a medium at 0.01 to 1000000 mg / L / day.
- the method according to [3], wherein the cell density of the cultured cells in the medium is 6 ⁇ 10 5 cells / mL or more.
- the medium composition according to [10], wherein the cell density of the cells to be suspended-cultured is 6.0 ⁇ 10 5 cells / mL or more.
- the medium composition according to [12], wherein the pluripotent stem cells are iPS cells.
- the medium composition according to any one of [8] to [13], wherein the cells are cells derived from iPS cells.
- cell proliferation can be easily promoted under high-density culture.
- suspension culture refers to a cell culture method performed in a state where cells do not adhere to a culture vessel.
- the suspension culture may or may not be accompanied by external pressure or vibration on the liquid medium, or shaking or rotation operation in the liquid medium.
- high density culture refers to culture at a cell density higher than that assumed in general cell culture. Dense criteria may differ depending on the kind or the like of the culture method (contact culture / suspension culture, etc.) and pluripotent stem cells, for example, the case of suspension culture iPS cells, 6 ⁇ 10 5 cells in this specification Culturing at a density of / mL or higher is defined as high density culture.
- pluripotent stem cell means a cell having the ability to differentiate into all the tissues and cells constituting the living body.
- pluripotent stem cells include, but are not limited to, embryonic stem cells (ES cells), embryonic germ cells (EG cells), and induced pluripotent stem cells (iPS cells).
- adult stem cell also referred to as somatic stem cell
- somatic stem cell means a cell having an ability to differentiate into a cell constituting a specific tissue (organ).
- adult stem cells include, but are not limited to, hematopoietic stem cells, nerve stem cells, reproductive stem cells, intestinal stem cells, epidermal stem cells, and mesenchymal stem cells.
- the "progenitor cell” means a cell in the process of differentiating from the pluripotent stem cell or adult stem cell described above into a specific somatic cell or germ cell.
- the present invention provides a cell culture method (hereinafter, may be referred to as “the method of the present invention”), which comprises adding choline to a medium at 0.01 to 1000000 mg / L / day. ..
- the choline used in the method of the present invention is not particularly limited as long as it is of a grade used for cell culture, and a commercially available product may be used. Suitable cholines include choline chloride, choline bitartrate, choline bicarbonate, choline phosphate, choline dihydrogen citrate and the like, with choline chloride being preferred.
- the amount of choline added to the medium is usually 0.01 to 1000000 mg / L / day, preferably 0.1 to 1000 mg / L / day, more preferably.
- Is 1 to 100 mg / L / day (for example, [1] 1 to 100 mg / L / day, 10 to 100 mg / L / day, 20 to 100 mg / L / day, 30 to 100 mg / L / day, 40 to 100 mg / L / day, 50 to 100 mg / L / day , 60-100 mg / L / day, 70-100 mg / L / day, 80-100 mg / L / day, 90-100 mg / L / day; [2] 1 to 90 mg / L / day, 10 to 90 mg / L / day, 20 to 90 mg / L / day, 30 to 90 mg / L / day, 40 to 90 mg / L / day, 50 to 90 mg / L / day; [2] 1 to 90 mg / L
- the medium used in the method of the present invention is not particularly limited, and a medium suitable for the cell type to be cultured can be used.
- a medium suitable for the cell type to be cultured can be used.
- Such a medium can be prepared by a method known per se, or a commercially available product may be used.
- DMEM Dulbecco's Modified Eagle's Medium
- F12 Ham's Nutrition Mixture F12
- DMEM / F12 medium McCoy's medium
- McCoy's McCoy's medium
- 5A Medium Minim's Essential Medium (MEM), Eagle's Minim's Essential Medium (EMEM), ⁇ 's Modified Eagle's Minim's Medium Essential Medium' ⁇ MEM), Roswell Park Memorial Institute (RPMI) 1640 medium, Iskov's Modified Dulbecco's Medium (IMDM), MCDB131 medium, William's Medium E (Willi's Medium) ), Fisher's Medium, and the like.
- STEMPRO registered trademark
- hESC SFM medium Life Technologies
- mTeSR1 medium STMCELL Technologies
- TeSR2 medium STMCELL Technologies
- TeSR2 medium STMCELL Technologies
- TeSR Essential 8 medium
- HESCGRO trademark
- Serum-Free Medium for hES cells Millipore
- PluristEM Human ES / iPS Medium
- EMD Medium
- EMD Medium
- EMD Medium
- EMD Medium
- EMD Medium
- EMD Medium
- EMD Medium
- EMD Medium
- EMD Medium
- EMD Medium
- EMD Biological Industries Israel Beat-Haemek
- NutriStem TM XF / FF Culture Medium Step
- AF NutriStem® hESC XF Medium Biomedical Medium Biological Medium
- Biologic Medium Co., Ltd.
- StemFit registered trademark
- components preferable for cell proliferation can be further added to these media.
- Such components include, for example, sugars such as glucose, fructose, sucrose, maltose; amino acids such as asparagine, aspartic acid, glutamine, glutamic acid; proteins such as albumin and transformin; peptides such as glycylglycylglycine and soybean peptide; serum; Vitamin such as choline, vitamin A, vitamin B group (thiamine, riboflavin, pyridoxin, cyanocobalamine, biotin, folic acid, pantothenic acid, nicotine amide, etc.), vitamin C, vitamin E; Lipids such as cholesterol; Inorganic salts such as sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium dihydrogen phosphate; trace elements such as zinc, copper, selenium; N, N-bis (2-hydroxyethyl) -2 -Aminoethanesulfonic acid (N, N-bis (2-
- Antibiotics such as; Type I collagen, Type II collagen, fibronectin, laminin, poly-L-lysine, poly-D-lysine and other cell adhesion factors and extracellular matrix components; interleukin, fibroblast growth factor (FGF) , Transforming Growth Factor (HGF), Transforming Growth Factor (TGF) - ⁇ , Transforming Growth Factor (TGF) - ⁇ , Vascular Endothelial Growth Factor (VEGF), Actibin A and other cytokines and growth factors; Examples thereof include hormones such as estradiol, progesterone, glucagon, and insulin, and an appropriate component can be selected and used according to the type of cells to be cultured.
- FGF fibroblast growth factor
- HGF Transforming Growth Factor
- TGF Transforming Growth Factor
- TGF Transforming Growth Factor
- TGF Transforming Growth Factor
- VEGF Vascular Endothelial Growth Factor
- Actibin A and other cytokines and growth factors
- examples thereof
- D-glucose and 5 amino acids may be additionally added to the medium.
- Glucose (or a salt thereof) is usually 0.1 g / L / day to 900 g / L / day, preferably 1 g / L / day to 200 g / L / day, more preferably 1 g / L in terms of glucose concentration. It can be added to the medium of the present invention so as to have a concentration of / day to 20 g / L / day.
- 5 kinds of amino acids are usually 0.1 mg / L / day to the concentration of tryptophan (concentration converted to free tryptophan) with respect to the medium.
- 11000 mg / L / day preferably 1 mg / L / day to 1000 mg / L / day, more preferably 1 mg / L / day to 100 mg / L / day, with a concentration of cysteine (concentration converted to free cysteine).
- 0.1 mg / L / day to 425,000 mg / L / day preferably 1 mg / L / day to 1000 mg / L / day, more preferably 1 mg / L / day to 100 mg / L / day, cysteine or cystine concentration ( The concentration converted to cysteine in the free form) is usually 0.1 mg / L / day to 280000 mg / L / day, preferably 1 mg / L / day to 1000 mg / L / day, and more preferably 1 mg / L / day to 100 mg.
- the concentration of methionine is usually 0.1 mg / L / day to 55000 mg / L / day, preferably 1 mg / L / day to 1000 mg / L / day, and more. It is preferably 1 mg / L / day to 100 mg / L / day, and the concentration of arginine (concentration converted to free arginine) is usually 0.1 mg / L / day to 150,000 mg / L / day, preferably 1 mg / L /. It can be added to the medium of the present invention so as to have a day to 2000 mg / L / day, more preferably 1 mg / L / day to 200 mg / L / day.
- the cell type to which the method of the present invention can be applied is not particularly limited.
- Such cell types include, for example, germ cells such as sperm and eggs, somatic cells constituting the living body, stem cells (pluripotent stem cells, etc.), precursor cells, cancer cells isolated from the living body, and immortalizing ability separated from the living body. Includes cells (cell lines) that acquire and are stably maintained in vitro, cells that have been isolated from the living body and artificially modified with genes, cells that have been separated from the living body and artificially exchanged nuclei, etc. ..
- somatic cells constituting the living body are not limited to the following, but are not limited to, fibroblasts, bone marrow cells, B lymphocytes, T lymphocytes, neutrophils, erythrocytes, platelets, macrophages, monospheres, and bones.
- Cells pericutaneous cells, dendritic cells, keratinocytes, fat cells, mesenchymal cells, epithelial cells, epidermal cells, endothelial cells, vascular endothelial cells, hepatic parenchymal cells, cartilage cells, oval cells, nervous system cells, glial cells, Neurons, oligodendrocytes, microglia, stellate collagen cells, heart cells, esophageal cells, muscle cells (eg, smooth muscle cells or skeletal muscle cells), pancreatic beta cells, melanin cells, hematopoietic precursor cells (eg, derived from umbilical cord blood) CD34 positive cells), mononuclear cells and the like.
- the somatic cells include, for example, skin, kidney, spleen, adrenal gland, liver, lung, ovary, pancreas, uterus, stomach, colon, small intestine, large intestine, bladder, prostate, testis, thoracic gland, muscle, connective tissue, bone, cartilage, blood vessels. Includes cells taken from any tissue such as tissue, blood (including cord blood), bone marrow, heart, eye, brain or nerve tissue.
- Stem cells are cells that have the ability to replicate themselves and differentiate into other multi-lineage cells, and examples include, but are not limited to, embryonic stem cells (ES cells). , Embryonic tumor cells, embryonic reproductive stem cells, artificial pluripotent stem cells (iPS cells), nerve stem cells, hematopoietic stem cells, mesenchymal stem cells, hepatic stem cells, pancreatic stem cells, muscle stem cells, reproductive stem cells, intestinal stem cells, cancer stem cells, Hair follicle stem cells and the like are included.
- ES cells embryonic stem cells
- iPS cells artificial pluripotent stem cells
- nerve stem cells hematopoietic stem cells
- mesenchymal stem cells mesenchymal stem cells
- hepatic stem cells pancreatic stem cells
- muscle stem cells reproductive stem cells
- intestinal stem cells intestinal stem cells
- cancer stem cells hair follicle stem cells and the like
- a cell line is a cell that has acquired infinite proliferative capacity by artificial manipulation in vitro, and examples thereof are, but are not limited to, CHO (Chinese hamster ovary cell line), HCT116. , Huh7, HEK293 (human fetal kidney cells), HeLa (human uterine cancer cell line), HepG2 (human liver cancer cell line), UT7 / TPO (human leukemia cell line), MDCK, MDBK, BHK, C-33A, HT- 29, AE-1, 3D9, Ns0 / 1, Jurkat, NIH3T3, PC12, S2, Sf9, Sf21, High Five (registered trademark), Vero and the like are included.
- CHO Choinese hamster ovary cell line
- HCT116. Huh7, HEK293 (human fetal kidney cells)
- HeLa human uterine cancer cell line
- HepG2 human liver cancer cell line
- UT7 / TPO human leukemia cell
- the cells can be, but are not limited to, pluripotent stem cells, adult stem cells, or progenitor cells.
- the cell can be a pluripotent stem cell.
- the pluripotent stem cell can be an embryonic stem cell (ES cell) or an iPS cell, preferably an iPS cell.
- ES cell embryonic stem cell
- iPS cell preferably an iPS cell.
- Adult stem cells can be, but are not limited to, hematopoietic stem cells, neural stem cells, reproductive stem cells, intestinal stem cells, epidermal stem cells, or mesenchymal stem cells.
- the origin of pluripotent stem cells, adult stem cells, and progenitor cells is also not particularly limited, but those derived from mammals are preferable, and those derived from humans are more preferable.
- the cell can be a cell derived from an iPS cell.
- the iPS cell-derived cell means a cell in the process of differentiating an iPS cell by a method known per se, or a differentiated cell.
- the culture conditions are not particularly limited, and a method known per se may be selected according to the cell type, cell density, culture method (adhesive culture / suspension culture, etc.) and the like.
- the culture temperature can be usually 25 ° C. to 39 ° C., preferably 33 ° C. to 39 ° C.
- the carbon dioxide concentration can be usually 4% by volume to 10% by volume, preferably 4% by volume to 6% by volume.
- the oxygen concentration may be usually 1% by volume to 25% by volume, preferably 4% by volume to 20% by volume.
- the present invention provides a cell culture medium composition (hereinafter, may be referred to as “the medium composition of the present invention”) containing 15 mg / L or more of choline.
- the medium composition of the present invention is characterized in that a high concentration of choline is added to a general basal medium for cells.
- the amount of choline contained in the medium for culturing cells is at most about 14 mg / L. This is because it is considered that the effect on cell proliferation is constant even if choline is added at a higher concentration.
- the lower limit of the concentration of choline contained in the medium composition of the present invention is usually 15 mg / L, preferably 16 mg / L, more preferably 17 mg / L, still more preferably 18 mg / L, and particularly preferably 20 mg / L. It is possible, and it may be more than this.
- the upper limit is not particularly limited, but from the viewpoint of cost and the like, it may be usually 1,000,000 mg / L, preferably 10000 mg / L, more preferably 1000 mg / L, still more preferably 100 mg / L, and particularly preferably 50 mg / L.
- the concentration of choline in the medium composition of the present invention is usually 15 mg / L to 1,000,000 mg / L, preferably 16 mg / L to 100,000 mg / L, more preferably 17 mg / L to 10000 mg / L, still more preferably 18 mg. It can be from / L to 100 mg / L, particularly preferably 20 mg / L to 50 mg / L.
- the medium for cells used in preparing the medium composition of the present invention may be prepared by a method known per se according to the cells to be cultured, or may be a commercially available product. ..
- the medium that can be used for producing the medium composition of the present invention, the components that can be further added to the medium composition of the present invention, and the cell types to which the medium composition of the present invention can be applied are described in "1. Cell culture method”. It is the same as that described in.
- iPS cells induced pluripotent stem cells
- iPS cells a 1210B2 strain purchased from iPS Academia Japan was used.
- a commercially available StemFit AK03N was used as a medium for iPS cells.
- Figure 1 shows the results of verifying the effect of choline on the proliferation of iPS cells in a single series. The addition of choline gave results showing a cell proliferation promoting effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
すなわち、本発明は以下の通りである。
[2]細胞培養が浮遊培養である、[1]記載の方法。
[3]高密度培養用である、[1]または[2]記載の方法。
[4]培養される細胞の培地中の細胞密度が6×105cells/mL以上である、[3]記載の方法。
[5]細胞が多能性幹細胞、成体幹細胞、または前駆細胞である、[1]~[4]のいずれか記載の方法。
[6]多能性幹細胞がiPS細胞である、[5]記載の方法。
[7]細胞がiPS細胞由来の細胞である、[1]~[4]のいずれか記載の方法。
[8]コリンを15mg/L以上含む、細胞培養培地組成物。
[9]浮遊培養用である、[8]記載の培地組成物。
[10]高密度培養用である、[8]または[9]記載の培地組成物。
[11]浮遊培養される細胞の細胞密度が6.0×105cells/mL以上である、[10]記載の培地組成物。
[12]細胞が、多能性幹細胞、成体幹細胞、または前駆細胞である、[8]~[11]のいずれか記載の培地組成物。
[13]多能性幹細胞がiPS細胞である、[12]記載の培地組成物。
[14]細胞がiPS細胞由来の細胞である、[8]~[13]のいずれか記載の培地組成物。
本明細書において、「浮遊培養」とは、培養容器に対して細胞が接着しない状態で行われる細胞培養方法をいう。本発明において、浮遊培養は、液体培地に対する外部からの圧力や振動、または、当該液体培地中での振とうや回転操作を伴ってもよいし、伴わなくてもよい。
本発明は、コリンを0.01~1000000mg/L/dayで培地に添加することを含む、細胞の培養方法(以下、「本発明の方法」と称することがある)を提供する。
[1]1~100mg/L/day、10~100mg/L/day、20~100mg/L/day、30~100mg/L/day、40~100mg/L/day、50~100mg/L/day、60~100mg/L/day、70~100mg/L/day、80~100mg/L/day、90~100mg/L/day;
[2]1~90mg/L/day、10~90mg/L/day、20~90mg/L/day、30~90mg/L/day、40~90mg/L/day、50~90mg/L/day、60~90mg/L/day、70~90mg/L/day、80~90mg/L/day;
[3]1~80mg/L/day、10~80mg/L/day、20~80mg/L/day、30~80mg/L/day、40~80mg/L/day、50~80mg/L/day、60~80mg/L/day、70~80mg/L/day;
[4]1~70mg/L/day、10~70mg/L/day、20~70mg/L/day、30~70mg/L/day、40~70mg/L/day、50~70mg/L/day、60~70mg/L/day;
[5]1~60mg/L/day、10~60mg/L/day、20~60mg/L/day、30~60mg/L/day、40~60mg/L/day、50~60mg/L/day;
[6]1~50mg/L/day、10~50mg/L/day、20~50mg/L/day、30~50mg/L/day、40~50mg/L/day;
[7]1~40mg/L/day、10~40mg/L/day、20~40mg/L/day、30~40mg/L/day;
[8]1~30mg/L/day、10~30mg/L/day、20~30mg/L/day;
[9]1~20mg/L/day、10~20mg/L/day)
とすることができる。
本発明は、コリンを15mg/L以上含む、細胞培養用培地組成物(以下、「本発明の培地組成物」と称することがある)を提供する。
以下の実施例では、コリンによる人工多能性幹細胞(iPS細胞)の増殖効果を評価した。iPS細胞として、iPSアカデミアジャパン社より購入した1210B2株を用いた。また、iPS細胞用培地として、市販のStemFit AK03N(味の素社)を用いた。
iPS細胞用30mLシングルユースバイオリアクター(ABLE: BWV-S03A)を用いて、StemFit AK03N+10μM Y-27632(Wako: 034-24024)にiPS細胞1210B2株を6×105cells/mLの細胞密度で播種し、CO2インキュベーター内で37℃、CO2濃度=5%、攪拌速度=120rpmの条件下で攪拌培養した。播種2日目に7割の培地をStemFit AK03Nで交換した。播種3日目に細胞懸濁液10mLを新鮮なStemFit AK03NまたはStemFit AK03N+10mg/L Choline Chloride (富士フイルム和光純薬社)に再懸濁し、マイクロバイオリアクターのambr15(sartorius:001-0881)に移し、37℃、pH=7.2、溶存酸素濃度=20%、攪拌速度=300rpmの条件下で攪拌培養を続けた。7割の培地をStemFit AK03NまたはStemFit AK03N+10mg/L Choline Chlorideで1日1回交換し、さらに両群に40mg/L/day Trp(味の素社)、40mg/L/day Ser(味の素社)、40mg/L/day Cys塩酸塩(日本プロテイン社)、40mg/L/day Met(味の素社)、160mg/L/day Arg(味の素社)、4g/L/day D-グルコース(ナカライテスク社:16806-25)を添加した。培養8日目に生細胞数を生死細胞オートアナライザーのVi-CELLTM XR(ベックマン・コールター社)を用いて測定した。
Claims (14)
- コリンを0.01~1000000mg/L/dayで培地に添加することを含む、細胞の培養方法。
- 細胞培養が浮遊培養である、請求項1記載の方法。
- 高密度培養用である、請求項1または2記載の方法。
- 培養される細胞の培地中の細胞密度が6×105cells/mL以上である、請求項3記載の方法。
- 細胞が多能性幹細胞、成体幹細胞、または前駆細胞である、請求項1~4のいずれか一項記載の方法。
- 多能性幹細胞がiPS細胞である、請求項5記載の方法。
- 細胞がiPS細胞由来の細胞である、請求項1~4のいずれか一項記載の方法。
- コリンを15mg/L以上含む、細胞培養培地組成物。
- 浮遊培養用である、請求項8記載の培地組成物。
- 高密度培養用である、請求項8または9記載の培地組成物。
- 浮遊培養される細胞の細胞密度が6.0×105cells/mL以上である、請求項10記載の培地組成物。
- 細胞が、多能性幹細胞、成体幹細胞、または前駆細胞である、請求項8~11のいずれか一項記載の培地組成物。
- 多能性幹細胞がiPS細胞である、請求項12記載の培地組成物。
- 細胞がiPS細胞由来の細胞である、請求項8~13のいずれか一項記載の培地組成物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21741902.7A EP4092105A4 (en) | 2020-01-14 | 2021-01-13 | METHOD FOR CULTURE OF HIGH DENSITY CELLS |
KR1020227028000A KR20220128645A (ko) | 2020-01-14 | 2021-01-13 | 세포의 고밀도 배양 방법 |
JP2021571195A JPWO2021145321A1 (ja) | 2020-01-14 | 2021-01-13 | |
CA3167733A CA3167733A1 (en) | 2020-01-14 | 2021-01-13 | High-density cell culture method |
CN202180010010.1A CN115003792A (zh) | 2020-01-14 | 2021-01-13 | 细胞的高密度培养方法 |
US17/863,785 US20220348883A1 (en) | 2020-01-14 | 2022-07-13 | High-density cell culture method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020003959 | 2020-01-14 | ||
JP2020-003959 | 2020-01-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/863,785 Continuation US20220348883A1 (en) | 2020-01-14 | 2022-07-13 | High-density cell culture method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021145321A1 true WO2021145321A1 (ja) | 2021-07-22 |
Family
ID=76864299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/000746 WO2021145321A1 (ja) | 2020-01-14 | 2021-01-13 | 細胞の高密度培養方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220348883A1 (ja) |
EP (1) | EP4092105A4 (ja) |
JP (1) | JPWO2021145321A1 (ja) |
KR (1) | KR20220128645A (ja) |
CN (1) | CN115003792A (ja) |
CA (1) | CA3167733A1 (ja) |
WO (1) | WO2021145321A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04501660A (ja) * | 1988-09-23 | 1992-03-26 | カイロン コーポレーション | 増強された細胞増殖、培養寿命および生産物発現のための細胞培養培地 |
JP2013524826A (ja) * | 2010-04-26 | 2013-06-20 | ノバルティス アーゲー | 改良型細胞培養培地 |
JP2016026490A (ja) * | 2014-06-27 | 2016-02-18 | 国立大学法人 千葉大学 | 多能性幹細胞から肝芽細胞を分化誘導する培養培地および方法 |
JP2018184352A (ja) | 2017-04-24 | 2018-11-22 | アサマ化成株式会社 | 抗体を有効成分とするtnf産生抑制作用組成物 |
JP2020003959A (ja) | 2018-06-26 | 2020-01-09 | 富士通株式会社 | 情報処理装置、演算処理装置及び情報処理装置の制御方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2251249B (en) * | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
JP2008099662A (ja) | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
US20160230143A1 (en) * | 2013-09-19 | 2016-08-11 | The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Chemically defined culture medium for stem cell maintenance and differentiation |
GB201700504D0 (en) * | 2017-01-11 | 2017-02-22 | Francis Crick Inst Ltd | Composition |
-
2021
- 2021-01-13 CA CA3167733A patent/CA3167733A1/en active Pending
- 2021-01-13 EP EP21741902.7A patent/EP4092105A4/en active Pending
- 2021-01-13 CN CN202180010010.1A patent/CN115003792A/zh active Pending
- 2021-01-13 KR KR1020227028000A patent/KR20220128645A/ko unknown
- 2021-01-13 JP JP2021571195A patent/JPWO2021145321A1/ja active Pending
- 2021-01-13 WO PCT/JP2021/000746 patent/WO2021145321A1/ja unknown
-
2022
- 2022-07-13 US US17/863,785 patent/US20220348883A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04501660A (ja) * | 1988-09-23 | 1992-03-26 | カイロン コーポレーション | 増強された細胞増殖、培養寿命および生産物発現のための細胞培養培地 |
JP2013524826A (ja) * | 2010-04-26 | 2013-06-20 | ノバルティス アーゲー | 改良型細胞培養培地 |
JP2016026490A (ja) * | 2014-06-27 | 2016-02-18 | 国立大学法人 千葉大学 | 多能性幹細胞から肝芽細胞を分化誘導する培養培地および方法 |
JP2018184352A (ja) | 2017-04-24 | 2018-11-22 | アサマ化成株式会社 | 抗体を有効成分とするtnf産生抑制作用組成物 |
JP2020003959A (ja) | 2018-06-26 | 2020-01-09 | 富士通株式会社 | 情報処理装置、演算処理装置及び情報処理装置の制御方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP4092105A4 |
Also Published As
Publication number | Publication date |
---|---|
CN115003792A (zh) | 2022-09-02 |
US20220348883A1 (en) | 2022-11-03 |
JPWO2021145321A1 (ja) | 2021-07-22 |
CA3167733A1 (en) | 2021-07-22 |
EP4092105A1 (en) | 2022-11-23 |
EP4092105A4 (en) | 2024-03-06 |
KR20220128645A (ko) | 2022-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103060264B (zh) | 一种干细胞培养基及其应用和干细胞培养方法 | |
Yang et al. | Culture conditions and types of growth media for mammalian cells | |
JP6990659B2 (ja) | がん幹細胞(csc)含有細胞集団の培養のための化学的に規定された培地 | |
CN105112361A (zh) | 用于细胞的生物反应器放大的细胞培养系统 | |
US20070148767A1 (en) | Method of forming multicellular spheroids from the cultured cells | |
US20210147794A1 (en) | Suspension culturing additive, suspension culturing medium and suspension culturing method for animal cells | |
CN115052970A (zh) | 培养基中纤维母细胞生长因子活化剂的使用 | |
US20210284971A1 (en) | Culture additive, culture medium and culture method for animal cells | |
David et al. | Co-culture approaches for cultivated meat production | |
WO2021145321A1 (ja) | 細胞の高密度培養方法 | |
US20230002729A1 (en) | Cell culture medium composition | |
WO2021145322A1 (ja) | 浸透圧低減培地 | |
WO2021145320A1 (ja) | 細胞の培養方法 | |
US20150329826A1 (en) | Materials and methods for cell culture | |
EP4130238A1 (en) | Hepes-containing medium | |
Major et al. | Mapping the microcarrier design pathway to modernise clinical mesenchymal stromal cell expansion | |
Taye et al. | Clinical Grade Stem Cell Culture | |
de Sousa Costa | Scalable production of human mesenchymal stem cells under xeno-free conditions for Cellular Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21741902 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021571195 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3167733 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021741902 Country of ref document: EP Effective date: 20220816 |